Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:37:48.811Z.
Calculation as of: 2026-10-06T20:37:48.811Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca628ff6f55b6345e2cefca22780bd34dfabddebf8a5c62bf0c86d2d29f40561
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Phio Pharmaceuticals Corp.
Market Cap
$11.55M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.12M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.08M
Price/OCF Ratio
N/A
TTM Avg
6.96
3Y Avg
6.96
5Y Avg
6.96
Market Cap
$12.06M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.02M
Price/OCF Ratio
N/A
TTM Avg
5.31
3Y Avg
5.31
5Y Avg
5.31
Market Cap
$11.00M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | $11.55M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $11.36M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $11.77M | N/A | 9.81 | 9.81 | 9.81 |
| Biofrontera Inc. (BFRI)vs › | $11.93M | N/A | N/A | N/A | N/A |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | N/A | 6.96 | 6.96 | 6.96 |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | N/A | 5.31 | 5.31 | 5.31 |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
